School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Satellos Bioscience Inc. MSLE

Healthcare · Biotechnology

$7.49last close 2026-10-09 · market cap $158.91M · delayed data

Trailing returns

1M-25.25%
3M-20.66%
6M+20.81%
1Y+7.80%
5Y-52.71%

Basis: Adjusted daily closes.

What it does

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

Open MSLE in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies